-
How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond
Monday, January 30, 2023 - 9:29am | 1080Florida-based BioStem Technologies, Inc. (OTCMKTS: BSEM) is a biotech company focused on developing and manufacturing structural-tissue allografts derived from perinatal tissues and intended for use as a protective covering for soft-tissue wounds. Perinatal tissue – an abundant source...
-
BioStem Reveals Plans For New Products, Expanded Sales And Manufacturing Capabilities At Dawson James Small Cap Growth Conference
Monday, January 23, 2023 - 9:26am | 1014Jason Matuszewski, CEO and co-founder of BioStem Technologies, Inc. (OTCMKTS: BSEM), presented at last year’s Dawson James Small Cap Growth Conference in October. BioStem is a biotech company developing tissue allografts from perinatal tissue — including umbilical cords, and placentas...
-
Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care
Tuesday, January 17, 2023 - 9:21am | 567Benzinga recently spoke to the CEO of BioStem Technologies, Inc. (OTCMKTS: BSEM) (“BioStem”), Jason Matuszewski, about his company’s mission and future. BioStem is a leading biotech innovator focused on harnessing the natural properties of perinatal tissue to help patients...
-
2022 Year in Review: BioStem Technologies Looks Back At A Year of Growth And Expansion
Friday, January 13, 2023 - 9:20am | 1034BioStem Technologies, Inc. (OTCQB: BSEM) is a Florida-based biotechnology company focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of structural tissue allografts for use as a protective covering for soft-tissue wounds. The year...
-
BioStem Aims To Stay Ahead Of Competition Through Its Unique Processes And Versatile Offerings In Wound Healing
Thursday, December 8, 2022 - 9:12am | 1069The human body has an amazing ability to heal itself, but the pace and extent of healing can vary dramatically from case to case, depending on the nature of the injury, site and the extent of tissue damage. The terms regenerative medicine and tissue engineering —where the body uses its...
-
How The Personal Experience Of This Biotech Company's Leadership Became The Cornerstone Of Its Growth Story
Monday, December 5, 2022 - 9:23am | 1072BioStem Technologies Inc. (OTCPK: BSEM) is a biotechnology company in the cutting-edge regenerative medicine field focused on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. Perinatal tissues are an...
-
Could BioStem's Perinatal Tissue-Based Products Be The Chronic Wound-Healing Solution Everyone Is Waiting For?
Thursday, November 3, 2022 - 1:19pm | 1013The treatment of chronic and acute wounds has always represented a major challenge in the healthcare field. Chronic wounds are defined as wounds that have failed to progress through the phases of healing in an orderly and timely fashion and have shown no significant progress toward healing in...
-
Could Perinatal Allografts Be Charting A New Course In Wound Healing?
Tuesday, October 25, 2022 - 8:26am | 928An allograft is tissue that is transplanted from one person to another. The prefix “allo” comes from a Greek word meaning “other.” An allograft is different from an autograft, which uses the individual's own tissue and is, therefore, genetically identical. Human...
-
BioStem Technologies (OTCMKTS: BSEM) Coverage Initiated at Zacks Investment Research
Thursday, September 22, 2022 - 4:50pm | 3722The below report was authored by Brad Sorensen, CFA, Zacks Small Cap Research. You can find the original report here. BioStem Technologies (OTCMKTS: BSEM) is changing the skin graft market by using the natural properties of perinatal tissue. Revenues are rising and...
-
BioStem Technologies, Inc. Second Quarter Financial Results Call, August 22, 2022
Friday, September 9, 2022 - 1:23pm | 3666C O R P O R A T E P A R T I C I P A N T S Nicolas Johnson, Russo Partners Jason Matuszewski, Chief Executive Officer Michael Fortunato, Controller C O N F E R E N C E C A L L P A R T I C I P A N T S Stefan Roaczek, Benzinga P R E S E N T A T I O N Operator Welcome to the...
-
BioStem Technologies Reports 133% Year-Over-Year Revenue Growth As It Expands Distribution of Patented Allograft Tech
Thursday, September 8, 2022 - 7:51am | 803BioStem Technologies Inc. (OTCMKTS: BSEM) is a regenerative medicine company that develops and manufactures tissue allografts for use in surgery and wound care. In August, the company reported growth exceeding even its own expectations as net revenue increased to $2.2 million for the second quarter...
-
BioStem Technologies' Local MicroEnvironment Activation Possible Key To Reversing And Repairing Diseases-Caused Tissue Damage
Thursday, June 23, 2022 - 9:07am | 107Jason Matuszewski, CEO of BioStem Technologies Inc. (OTCMKTS: BSEM), was a guest speaker at Benzinga’s All Access on June 17th, 2022. BioStem Technologies Inc. is a pre-clinical-stage biotechnology company that has developed a proprietary approach, called Local MicroEnvironment...